Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

30 Sep 2019

588.80

0.35%

SAST

Laurus Labs Ltd - 540222 - Closure of Trading Window

BSE India

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and the circular issued by the Stock Exchanges, the trading window for dealing in the shares of the Company shall remain closed from October 01, 2019 till 48 hours after the declaration of un-audited financial results for the quarter and half-year ended September 30, 2019. The date of Board Meeting of the Company for consideration and approval of the un-audited financial results for the quarter and half-year ended September 30, 2019 will be intimated later.

pdf

Laurus Labs Ltd.

24 Sep 2019

588.80

0.35%

SAST

Laurus Labs Ltd - 540222 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, …

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Chunduru Venkata Lakshmana Rao

pdf

Laurus Labs Ltd.

24 Sep 2019

588.80

0.35%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

BSE India

This is to inform you that the Nomination & Remuneration Committee of Board of Directors of the Company has allotted on September 24, 2019 by way of resolution by circulation 3,10,500 Equity Shares of Rs.10/- each of the Company, fully paid up, at a price of Rs.10/- each, to the eligible Employees on exercise of their Stock Options under Laurus Employees Stock Option Scheme, 2011. This is to further inform you that the Nomination & Remuneration Committee of Board of Directors of the Company has allotted on September 24, 2019 by way of resolution by circulation 1,67,250 Equity Shares of Rs.10/- each of the Company, fully paid up, at a price of Rs.137.50 per share (including premium of Rs.127.50 per share), to the eligible Employees on exercise of their Stock Options under Laurus Employees Stock Option Scheme, 2016. The total paid up capital of the Company after the above allotments stands at Rs.106,91,44,990.

pdf

Laurus Labs Ltd.

18 Sep 2019

588.80

0.35%

Company Update

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

This is to inform you that Laurus Labs Limited has agreed to acquire 100% shares of Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary company of Pharmacare Limited t/a Aspen Pharmacare, South Africa, subject to completion of conditions precedent, by way of cash consideration of ZAR 75,000 (Seventy-five thousand South African Rand). At the conclusion of the transaction, all residual assets and liabilities that are within the target company immediately prior to completion will be for Pharmacare Limited's account and accordingly all such assets and liabilities will be transferred from the target company to Pharmacare Limited immediately prior to completion.

pdf

Laurus Labs Ltd.

18 Sep 2019

588.80

0.35%

Company Update

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

The Company is pleased to announce that it has agreed to acquire 100% shares of Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary company of Pharmacare Ltd. t/a Aspen Pharmacare, South Africa, subject to completion of conditions precedent, by way of cash consideration of ZAR 75,000 (Seventy-five thousand South African Rands). The acquisition is expected to be completed by end of November, 2019. At the conclusion of the transaction, all residual assets and liabilities that are within the target company immediately prior to completion will be for Pharmacare Limited's account and accordingly all such assets and liabilities will be transferred from the target company to Pharmacare Limited immediately prior to completion. A press release to this extent is also attached for your information and records.

pdf

Laurus Labs Ltd.

05 Sep 2019

588.80

0.35%

Company Update

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

The Company is pleased to announce that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019. And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy). A press release to this extent is attached for your information and records.

pdf

Laurus Labs Ltd.

20 Aug 2019

588.80

0.35%

Company Update

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Laurus Labs Intimates, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations'), the details of Analyst/Institutional Investor meeting to be conducted on August 21, 2019.

pdf

Laurus Labs Ltd.

08 Aug 2019, 10:48AM

588.80

0.35%

Earnings Call

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Laurus Labs Q1 FY2020 Earnings Conference Call August 05, 2019 transcript

pdf

Laurus Labs Ltd.

02 Aug 2019

588.80

0.35%

Investor Presentation

Laurus Labs Ltd - 540222 - Laurus Labs Investors/Analysts Presentation On The Unaudited Financial Results Of …

BSE India

We enclose herewith the presentation to the Investors/Analysts on the Unaudited Financial Results of the Company for the Quarter ended June 30, 2019, for the Investors/Analysts call scheduled on August 05, 2019, which was already intimated on July 30, 2019. The presentation is also being uploaded on the website of the Company www.lauruslabs.com. Please take the information on record.

pdf